PDI Wants To Help Small Pharma Develop Products In-House
This article was originally published in The Pink Sheet Daily
Executive Summary
Contract sales provider wants to diversify into small pharma services as big pharma cuts back outsourced sales reps.
You may also be interested in...
Sanofi-Aventis Ends PDI Sales Contract
Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.
PDI Expands Into Physician Audioconference Marketing With Pharmakon Acquisition
The $30 mil. acquisition will diversify revenue and expand marketing capabilities, PDI says. Once the deal closes, the company will have over $90 mil. in cash to pursue additional acquisitions.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: